Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T therapy shows promise for cancer treatment.
• Current CAR-T limitations include restricted versatility, tractability, and lack of exclusive target antigens.
• Need for enhanced control over CAR-T cell function is critical.

Purpose of the Study:

• To engineer the Adapter CAR (AdCAR) system for temporal and qualitative control of CAR-T function.
• To develop a versatile and adaptable CAR-T platform for cancer therapy.

Main Methods:

• Engineered the Adapter CAR (AdCAR) system utilizing a Linker-Label-Epitope structure.
• Redirected AdCAR-T cells to target surface antigens via biotin-labeled adapter molecules.
• Evaluated AdCAR-T efficacy and specificity in preclinical mouse models.

Main Results:

• AdCAR-T cells demonstrated highly specific and controllable effector functions against multiple target antigens.
• AdCAR-T therapy durably eliminated aggressive lymphoma in mouse models.
• The system showed potential for preventing antigen escape through combinatorial targeting and differential lysis based on multiplex antigen profiles.

Conclusions:

• The AdCAR technology provides controllable, flexible, combinatorial, and selective targeting capabilities for CAR-T cell therapy.
• AdCAR-T offers a promising strategy to overcome limitations of current CAR-T approaches.
• This adaptable platform has the potential to broaden the applicability of CAR-T cell therapies in oncology.